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Although iamivudine has been successfully used to
treat hepatitis B reactivation in cancer oatients its role
as prophy/axis in these patients is less well defined.
We describe successful lamivudine prophylaxis of
a patient with chronic hepatitis B undergoing chemo
therapy for acute myelogenous leukemia (A ML). We
support the position that lamivudine may playa signifi
cant role in the successful prevention of reactivation
hepatitis B in cancer patients undergoing cherno
ther.apv.
The views espressedin this manuscript are those of
the authors and do not reflect the official policy or
positIon of the Department of the Army. Department of
Defense. or the LI S. Government
Introduction
Reactivation hepatiti sB in cancer patients undergoing
chemotherapy is well documented in the literature. In
the setting of chemotherapy-induced immunosuppres
sion, reactivation of hepatitis B can lead to a spectrum
of adverse outcomes including fulminant hepatic fail
ure and death. Lamivudine, a reverse transcriptase
inhibitor, has been used to treat reacti\ ation hepatitis
in this subset of patients. Although prophvlaxis is
otten suggested. reports arc rare. We describe success
ful lamivudine prophvlaxis of a patient with chronic
hepatitis B undersoing chemotherapy for acute mvel—
ogenous leukemia (
Case Report
The patient is a 25-year-old female with chronic
hepatitis B who was diagnosed with AML after evalu
ation for buccal ecchymosis and extremity hemato
mas. Initial labs were remarkable for hepatitis B
surface antigen ([IBsAg) reactivity, hepatitis B virus
if-lB V) DNA ol .1)3 pg/mI, aspartate arniuotransferase
i .-\ST)of69 [IL. and alanine arninotransferase (ALT)
of h2 [/L.
She began prophv lactic treatment ss ith lamivudine
prior to induction chemotherapy with daruhicin and
cvtarabine. Proph axis was continued throughout the
subsequent consolidation chemotherap . which in
cluded fourc clesofhieh dosec tatabinc. \side from
ses erul episodes of neutropenic fes er. she tolerated
the chemotheraps well. Althou 11 the patient hid
persistentl\ I ated li\ er associ t d en/\ mes \l T
tingin om 68 to 7 1 IL and AST ran ‘ing 1mm
to ISO [IL) HB\ DN \ 1ev 1 r tn in d undetei.. abl
and th pan nt had no clint all si nih ant h pati
equ lae.
Dut im h r ninth month of trcatm nt th pati nt had
a Pt olony d p nod of panc top ma v ith hone mat to
hiops show in a i elapse of her AvlI . \ftei failed
teinduction with mito\antrone and etoposide. the pa
tient was schduled for an al Iogenetc bone mat row
transplant. At that time, the patient’s li er associated
en/i mes included an AST of O [IL and an \1 Tot 6%
f-/I . HBV DNA leels were still undetectable. 1 he
highest le els of transaminases occurred during in
duction and retnduction and were thouuht secondary
to chemotheraps induced hepatoto icit (Figure h
Discussion
A spectrum of liver injury is associated with chemo
therapy, ranging, from anicteric hepatitis to fulminant
hepatic failure and death. Etiologies include viral
hepatttts. drug hepatoto\icitv. malignant hepatic tnftl—
trat it ‘n. shock, sepsi. and crvptovenic cause.A grow
ing body of’ literature has concentrated on the ad ersc
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Reacti ation hepatitis B in cancer patients receiving
cvtotoxic chemotherapy is vell reported. Although
most cases have involved hematological rnalignan—
cies (ie. lvmphomaL occasional cases involving solid
tumors ha e been reported as well. In a I 991 retro
spective study of Chinese lvmphoma patients. 27%
were found to he HBsAg seropositive. Of these pa
tients, 47% developed reactivation hepatitis during
chemotherapy. which resulted in a 5% mortality.2 In
a similar Japanese study. 3.3% of lymphoma patients
were found to have chronic HBV infection .Seere
hepatitis occurred in 53% of these patients and mortal—
tv rates were as high as 24%. In 2000. Yeo et al.
conducted the first prospective assessment of HBV
reactivation rates in Chinese cancer patients recei ing
c\totoxic chemotherap. In this study. 12% of 626
consecutive cancerpatients were HBsAg positive, and
reactivation occurred in nearly 20% of these patients.
This data clearly supports the need for in depth assess
ment of this adverse process. Of note, hepatitis C
injection has also been documented in association
with chemotherap —induced hepatitis. and mortalit\
rates appear to he similar to that seen in patients with
HBV reactivation.
There are two proposed mechanisms ofreactivation
hepatitis B in cancer patients undergoing c totoxic
chemotherapy. The first involves immunosuppres—
sion, enhanced KBV replication, and direct hepato
toxicity from infection. The second mechanism in
volves a rebound immune response upon withdrawal
ofchernotherapv. resulting in hepatocyte destruction.
Attempts to identify risk factors for reactivation
hepatitis B ha e produced conflicting results. A 190
study of 105 lvmphoma patients b Liang et al. con—
eluded that age, sex, stage. symptoms. lvmphoma
subtype. presence of hepatic lvinphoma. treatment.
presence of HBcAg and anti-H13e serologies. and
underlying liver pathology \ere not predictive of
hepatic complications.5However, a prospective study
by Yeo et al. identified several significant associated
factors. These included male sex, younger age. pres
ence of lymphoma. chernotherapeutic agent (most
common being corticosteroids. anthracvclincs. cvclo—
phosphamide. and ‘ inca alkaloids), and HBeAg posi—
ti\ itv (although %ome virulent precore mutant strains
are unable to produce the eAg and are still highly
associated v ith fulminant hepatic failure
Perhaps the most promising treatment for reactiva
tion hepatitis in cancerpatients is the use of lami udine
(3-thiacytidine), areverse transcriptase inhibitor, This
nucleoside analog, originally used for HJV infection,
was found to reduce KBV DNA to undetectable les els
in 86% of I-IlV infected HBV carriers ithin t o
months. Several successful pilot studies and four
large multicenter randomized control led trials sho’ ed
that lamivudine therapy va’ associated with an in—
creased tate of HBeAc serocon\ erion. impro ed
serunt ALT levels and liver histology, and a decrease
in the development of eiThosis.’
- In addition to its
efficacy. lamivudine was associated with few if any
side etfects.r The drug was approved as therapy for
HBeAg positi e chronic hepatitis B patients in 1998.
Lamivudine’s role has subsequently been broadened
to treat chemotherapy-induced reactivation hepatitis
B. There are at least 13 documented case reports of
successful lamivudine treatment of reactivation hepa
titis. including those patients with fulminant disease.4
Lamivudine may also play an important role as
proph laxis for chronic HBV cancer patients prior to
chemotherap . B’ suppressing HBV DNA replication
(as evidenced by histology and HBV DNA levels).
lami vudine prevents hepatocvte infection, the rebound
immune response. and subsequent reacti\ ation hepa
titis. Several case reports (including our own) and two
recent studies, give direct support to this proposal.8
In our patient, HBV DNA levels remained undetect
able throughout chemotherapy, and transient eleva
tions in her liver enzymes were secondary to chemo
therap —induced hepatotoxieitv. In a retrospective Is
raeli study. 13 FIBV infected cancer patients were
prophylactically treated with lamivudine prior to and
follo ing immunosuppressive therapy, with a mean
follow—up of 2 1 months. None of the patients had
clinical or serological evidence of HBV reactivation
during or after prophvlaxis. Likewise, in a prospective
Italian study, 20 consecutive patients with HBV and
hematologic malignancies were prophylactically
treated with 100 mg of lamivudine from the start of
chemotherapy until one month after the end of treat
ment. Only one patient developed reactivation hepati
tis during a median follow—up of six months.
Several unresolved issues regarding lamivudine
prophvlaxis need to he addressed. Specificaii. opti
mal dose, duration of therapy, and resistance have
been investigated in chronic HBV patients, but not in
those patients undergoing chemotherapy. In a one
year trial of lamivudine. Lai et al. showed that 100mg
daily was more effective than 25 mg in the extent of
histologic improvement, degree of HBV DNA sup
pression. and prevention of fihrosi.
- Duration of
therapy and resistance have also been studied exten
sivel . as prolonged lamivudine therap allows for
genot pie mutations in the YMDD locus of HBV that
confers a reduced sensitivity to lamivudine, Resis
tance rates at one, two. three, and four years are 17%.
40%, 55%, and 67%. respectively. These patients
typically have higher ALT and HBV DNA levels than
those ithout resistance. but levels on average are still
lower in affected indi iduals than their pretreatment
alues. Continued histologic improvement is also
seen ith extended therap regardless of YMDD
resistance, as evidenced by liver biopsies from pa
tients treated with t o or more years of lamivudine in
the .\%ian 1uiticenter trial.
- In addition. a large co—
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hon study showed no increased incidence of hepatic
insufficiency or change in adverse events noted with
the YMDD mutant I-IBV. Therefore, while prophy
laxis nn ith 100mg of larnivudine for extended periods
of time seems safe and effective in chronic HBV
patients despite YMDD resistance. randomized double-
blinded trials will be needed to better assess these
issues in cancer patients undergoing cvtotoxicchemo
therapy
Conclusion
There are 400 million cases of hepatitis B worlcks ide
with prevalence rates in chemotherapy patients re
ported at 12%. Reactivation hepatitis occurs in 20-
50% of these patients and is a potentially lethal com
plication, with mortality rates documented as high as
25% in affected individuals. Lamivudine therapy,
originally used in HIV patients and then approved for
HBeAg chronic HBV, has now been used to success
fully treat reactivation hepatitis B in chemotherapy
patients. We support the position that lamivudine
should also be used as prophylaxis to prevent reactiva
tion hepatitis in cancer patients, and we provide a case
report of successful lamivudine prophylaxis.
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